Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $67.60 Average Target Price from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $67.60.

A number of brokerages have weighed in on ARCT. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, July 2nd. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Finally, Canaccord Genuity Group decreased their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, May 10th.

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total value of $1,040,260.00. Following the transaction, the chief operating officer now directly owns 447,448 shares of the company’s stock, valued at $17,902,394.48. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares during the period. Arizona State Retirement System acquired a new position in shares of Arcturus Therapeutics in the 4th quarter valued at $211,000. Tritonpoint Wealth LLC bought a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at $885,000. DekaBank Deutsche Girozentrale increased its stake in Arcturus Therapeutics by 3.0% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 43,889 shares of the biotechnology company’s stock worth $1,401,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Arcturus Therapeutics by 224.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 114,810 shares of the biotechnology company’s stock worth $3,620,000 after buying an additional 79,387 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

ARCT opened at $20.55 on Friday. The firm’s fifty day moving average price is $27.52 and its two-hundred day moving average price is $31.10. The company has a market capitalization of $553.41 million, a P/E ratio of -5.26 and a beta of 2.64. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. On average, equities research analysts expect that Arcturus Therapeutics will post -4.74 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.